about
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis.Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Treatment of rheumatoid arthritis with tumour necrosis factor inhibitorsCause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.Impact of Bariatric Surgery on Patients With Rheumatoid ArthritisA Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyCanadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Antimicrobial dosing in acute renal replacement.Infliximab in the treatment of rheumatoid arthritisPopulation pharmacokinetic analysis of infliximab in patients with ulcerative colitis.Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel DiseasePractical aspects of prescribing a biologic.Focus on skin cancer association and progression under TNF antagonist therapy.Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis.The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review.European evidence based consensus on surgery for ulcerative colitis.Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.The power of observation.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Optimizing biological therapy in Crohn's disease.Tumor necrosis factor inhibitors in psoriatic arthritis.Biosimilar DMARDs: What Does the Future Hold?Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Predictors of long-term drug survival for infliximab in psoriasis.Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassaysDoes infliximab increase complications after surgery for inflammatory bowel disease?Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease.Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Defining and characterizing sustained remission in patients with rheumatoid arthritis.Infliximab for the treatment of ulcerative colitis.
P2860
Q33881234-CAE0DE36-C139-4BD1-AE98-8025DEEA6A37Q34222693-E99FCA7A-CCC6-4BFC-96C4-2EB6814B3DCBQ34476049-24201B6B-A628-4C0E-A9B8-E9AF3395AF3BQ34588629-F94B8EFD-DB1B-48AB-9799-E15FF9E64AF0Q35026302-02163340-D2E8-4F24-8B86-A240314A72B1Q35640448-A0D86758-3F29-443E-959B-8AB4F8055A5EQ36326901-CFD7610E-3D07-4EC9-9483-81B90E4B7525Q36385544-0F4005EC-5F00-4D9C-9D6C-9B37312E5954Q37197292-9EF38272-1BB5-4A73-9029-8B50C439011FQ37206628-A6B846BB-7043-450E-BB61-645E284A7A31Q37223169-90FDD39A-3CCB-48F2-B34D-4DCAE778C559Q37252494-842D341A-CF0E-4023-8BF9-1F6317B09D7BQ37303230-2CD610D6-EFF9-4328-BCDC-CA51CA5140E5Q37424635-BCA8869B-B59D-465A-903F-FBF5645BA60BQ37573910-95311F21-07BE-4355-AA46-200C856F8EBBQ37607426-E6F23183-06C9-4C65-817D-E4EF5C69DDE6Q37901473-48F40A98-3DD9-4F8C-9E43-BE0817E333FFQ37965581-3086206A-F8F4-40E0-9F7B-DEA6B3B8D9DDQ37998988-C6F50D2B-C471-4E09-B157-F8B2E65BACA1Q38193751-D81A1E6E-3A21-4935-B23A-308F31107327Q38258954-EC204E92-BF81-4C69-B01B-5F32D99D69A4Q38286010-A5B2D1D9-1376-4063-9305-789ADDAA688BQ38333638-1823DF24-A5E2-4172-9AE5-7563A3E61C97Q38365041-A7A2527F-B084-4FB2-A30D-1EB6183A506AQ38608158-E06D9414-5BC3-4DC7-A36E-4DCE58386DBCQ38685543-501DD14D-0D73-477B-94D3-4B96E04620CEQ38760042-FC7D95A7-862A-44E1-AF31-884C4B4FA18CQ38826447-0C67A3A4-3C8D-42BD-A554-0CEC3FB531CCQ38973323-68E8DE9D-0B17-4997-BD4E-F6345073EF25Q39030608-944EFC43-A132-4F6F-91F8-1000B749F818Q39668241-CEF86AA4-FF4C-498C-8A58-4CAD8D26A36AQ40112268-A4BEF164-7FA1-4063-B1E6-67001D9879BEQ41078498-5AA5944C-BC36-4C2D-B878-25B98842901EQ41876389-2D0D47CF-E902-43BB-8DC7-1DE01F1BED1BQ42551648-6566CA58-3E7E-4CF1-838E-01A58A7B78E0Q43058656-08A95A8D-6C21-460E-9E79-0813B72BE2C0Q44750379-FD7EA7E0-5EF7-4AB6-B538-E65903818512Q46866013-F0EE85EC-195A-4F4C-9FCE-2AAA2E281A57Q47336584-8C8469D9-8E2E-45E5-9CEF-34F439738899Q47682064-463C8161-D884-44B2-882B-A22705C83C13
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical pharmacokinetics and use of infliximab.
@en
type
label
Clinical pharmacokinetics and use of infliximab.
@en
prefLabel
Clinical pharmacokinetics and use of infliximab.
@en
P2093
P1476
Clinical pharmacokinetics and use of infliximab.
@en
P2093
Alexander Teml
Matthias Schwab
Ulrich Klotz
P304
P356
10.2165/00003088-200746080-00002
P577
2007-01-01T00:00:00Z
P6179
1047302694